UniQure has announced its intention to seek FDA approval for its experimental gene therapy targeting Huntington’s disease, following new guidance from the agency. This development comes months after previous leaders at the FDA raised concerns regarding the sufficiency of the evidence supporting the application. In a recent meeting, the FDA indicated that a three-year analysis from a Phase 1/2 study could facilitate accelerated approval of UniQure’s therapy for this hereditary condition, which progressively damages brain nerve cells. Consequently, UniQure plans to submit its application in the third quarter of this year.
An FDA spokesperson confirmed that the agency has reached an agreement with UniQure on a regulatory pathway for the marketing application, emphasizing its commitment to uphold high scientific standards while serving patients and their families. Following this positive feedback, shares of UniQure surged by 70% on the day of the announcement.
This represents a notable shift from earlier in the year, when the FDA expressed skepticism about UniQure’s trial data. At that time, critics suggested that additional placebo-controlled trials were needed to validate the therapy’s efficacy. The process of directly administering the gene therapy into the brain involves a lengthy surgical procedure, which UniQure argued would be unethical to replicate with a placebo.
With the FDA’s support, UniQure intends to utilize the previously scrutinized data to bolster its application. The agency is also keen on collaborating with the company to refine the design of a follow-up study that compares the new treatment with current standard care rather than a sham.
Why this story matters:
- Represents potential advancements in treatment options for Huntington’s disease.
- Highlights changes in FDA regulatory stance under new leadership.
Key takeaway:
- UniQure’s gene therapy could receive accelerated approval based on existing data, pending further study design agreement.
Opposing viewpoint:
- Concerns remain about the adequacy of clinical trial data to assure efficacy and safety for patients.
